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Abstract
Background: NUCKS (Nuclear, Casein Kinase and Cyclin-dependent Kinase Substrate) is a nuclear, DNA-binding and
highly phosphorylated protein. A number of reports show that NUCKS is highly expressed on the level of mRNA in
several human cancers, including breast cancer. In this work, NUCKS expression on both RNA and protein levels was
studied in breast tissue biopsies consisted of invasive carcinomas, intraductal proliferative lesions, benign epithelial
proliferations and fibroadenomas, as well as in primary cultures derived from the above biopsies. Specifically, in order to
evaluate the level of NUCKS protein in correlation with the histopathological features of breast disease,
immunohistochemistry was employed on paraffin sections of breast biopsies of the above types. In addition, NUCKS
expression was studied by means of Reverse Transcription PCR (RT-PCR), real-time PCR (qRT-PCR) and Western
immunoblot analyses in the primary cell cultures developed from the same biopsies.
Results: The immunohistochemical Results showed intense NUCKS staining mostly in grade I and II breast carcinomas
compared to normal tissues. Furthermore, NUCKS was moderate expressed in benign epithelial proliferations, such as
adenosis and sclerosing adenosis, and highly expressed in intraductal lesions, specifically in ductal carcinomas in situ
(DCIS). It is worth noting that all the fibroadenoma tissues examined were negative for NUCKS staining. RT-PCR and
qRT-PCR showed an increase of NUCKS expression in cells derived from primary cultures of proliferative lesions and
cancerous tissues compared to the ones derived from normal breast tissues and fibroadenomas. This increase was also
confirmed by Western immunoblot analysis. Although NUCKS is a cell cycle related protein, its expression does not
correlate with Ki67 expression, neither in tissue sections nor in primary cell cultures.
Conclusion: The results show overexpression of the NUCKS protein in a number of non malignant breast lesions and
cancerous tissues. In particular, the NUCKS overexpression in ADH and DCIS indicates a significant role of this protein
in neoplastic progression.
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NUCKS (Nuclear, Casein Kinase and Cyclin-dependent
kinase Substrate) is a nuclear, DNA-binding and highly
phosphorylated protein. It has been shown that NUCKS is
a substrate for CK2, Cdk1 and DNA-activated Kinase in
vitro and in vivo [1-4]. Proteomic studies have revealed 25
phosphorylation sites and multiple sites of acetylation,
methylation and formylation, suggesting that NUCKS has
the highest ratio of modified to unmodified residues of
any protein so far described [5]. The NUCKS gene is
located on chromosome 1q32.1, lacks a TATA box but
contains two Inr elements, two GC boxes and one consen-
sus binding site for E2F1. Although the level varies, the
NUCKS gene is ubiquitously expressed in all mammalian
tissues and has many features of being a housekeeping
gene [6]. NUCKS has been characterized as a cell cycle
related protein that is synthesized in the M/G1 phase [7].
Even though it appears to be important for cell cycle pro-
gression, its exact role has not been yet clearly understood.
A number of reports show that NUCKS is highly expressed
in several human cancers (ovarian, lung, bone marrow,
brain) including breast cancer [8-10]. NUCKS gene
belongs to a module of co-expressed genes located on
chromosomal region 1q32.1, which is found to be ampli-
fied in breast cancer [10], as well as in other cancers
[11,12]. Evidence that NUCKS is overexpressed in breast
cancer with a possible role in regulating transcriptional
regulation, makes it an excellent candidate molecule for
study [8]. Moreover, it has been shown that NUCKS is
overexpressed in post-selection human mammary epithe-
lial cells (HMEC), an in vitro model of highly dysregu-
lated epithelial cells with gene expression patterns highly
similar to that of ductal carcinoma in situ (DCIS) and
invasive breast cancer [13]. Furthermore, translational
modifications of NUCKS revealed acetylation and methyl-
ation sites specific for breast cancer, resembling the data
from core histones [5]. The above mentioned experimen-
tal data suggest that there is a relationship between
NUCKS overexpression and breast cancer. However, no
comprehensive study has been published up to day con-
cerning the correlation of NUCKS expression with the his-
topathological type (i.e. DCIS, IDC, etc) and the tumor
grading of breast cancer. In addition, all studies published
so far, refer to the expression of mRNA, and there are no
reports on the level of the NUCKS protein in different
types of breast lesions.
In the present study, NUCKS expression has therefore
been investigated in benign lesions, intraductal lesions
and invasive carcinomas by means of immunohistochem-
istry, and in primary cell cultures of breast biopsies by
measuring the levels of NUCKS mRNA and protein. Pri-
mary cell cultures have been developed from tissue frag-
ments isolated directly from the tumor site, according to
explant technique reflecting most of the aspects of tumor
profile compared to established cell lines [14]. The results,
taken altogether, show that NUCKS is overexpressed in
the majority of invasive carcinomas and intraductal prolif-
erations, mainly in DCIS.
Results
NUCKS immunolocalization
The distribution of breast tissue samples according to the
histopathological type and grade is presented in Addi-
tional file 1.
All the fibroadenoma cases (13/13) as well as the normal
tissues that were examined, stained negatively for NUCKS
(Table 1, Figures 1A, 1B). In the benign proliferative
lesions examined, NUCKS was expressed in 17/23 (85%)
cases of adenosis and 10/11 (91%) cases of sclerosing ade-
nosis (Table 1, Figure 1C) exhibiting moderate staining.
In the intraductal proliferative lesions, NUCKS was
expressed in 13/16 (81%) cases of usual ductal hyperpla-
sia (UDH), in 6/6 (100%) cases of atypical ductal hyper-
plasia (ADH) and in 15/16 (94%) cases of DCIS,
exhibiting intense staining in the majority of ADH and
DCIS (83% and 82% of the cases respectively stained with
a score of +2/+3) (Table 1, Figures 1D, 2A).
Concerning the benign breast diseases examined, some of
them are more closely linked to breast cancer risk than
others. According to World Health Organization (WHO)
[15], adenosis and sclerosing adenosis are not associated
with increased risk of subsequent carcinoma. In addition,
UDH is associated with a slightly elevated risk, although
not considered a precursor lesion. On the other hand,
ADH is associated with a moderately increased relative
risk (RR 4.0–5.0) while DCIS is considered a precursor
lesion (obligate or non-obligate) with a RR of 8.0–11.0
for the development of breast cancer. The results showed
that NUCKS is highly expressed in ADH and DCIS, char-
acterized of higher RR (approximately 83% of cases
stained with a score of +2/+3), compared to UDH and
adenosis/sclerosing adenosis, characterized of low RR
(approximately 35% of cases stained with a score of +2/
+3).
In breast carcinomas, the majority of the cases were
stained positively for NUCKS. In grade I carcinomas, 6/9
(66.5%) cases stained positively whereas in grade II, 37/
41 (90%) cases stained positively for NUCKS (Table 2,
Figure 2B). In IDC, grade III, although most of the cases
stained positively for NUCKS (6/8, 75%), the observed
immunoreaction was low (7/8, 87.5%) (Table 2, Figure
2C).
Among the breast carcinoma cases examined, there was a
relatively small number of lobular carcinomas, which inPage 2 of 14
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NUCKS. More specifically, there was one case of ILC,
grade I, which was negative for NUCKS staining and 6
cases of ILC, grade II, of which 2/6 (33%) stained nega-
tively, 2/6 (33%) low and 2/6 (33%) moderately.
Statistical analysis of all data showed no significant asso-
ciation between NUCKS expression and the ER, PR and
HER-2/neu status of the tumors (p = 0.45; p = 0.51; p =
0.74 respectively). Furthermore, NUCKS expression was
not associated with lymph node metastasis (p = 0.49).
Primary cultures
Using the explant technique, the majority of cell popula-
tion consists of epithelial cells since the majority of stro-
mal cells do not migrate out of the tissue. Supplementary,
morphometric analysis of each culture, revealed a small
percentage of fibroblasts (<5–8%) in the entire cell popu-
lation. The morphological examination of the primary
culture cells with the inverted microscope, under phase-
contrast field, demonstrated a typical neoplastic epithelial
morphology for the majority of the tumor-derived cells
(Figure 3A). They were characterized of polygonal shape
with large pleomorphic nuclei and prominent nucleoli. At
the ultrastructural level (Figure 3B), the epithelial neo-
plastic cells were attached to each other with tight junc-
tions and desmosomes. In addition, intercellular lumina
were often formed with protruding microvilli into the
lumen. The epithelial origin of the cells was also verified
by the CK8 immunofluorescence applied on the primary
culture cells. The results showed CK8 immunofluores-
cence of varied intensity in the cytoplasm of the entire cell
population (Figure 3C).
Semi-quantitative NUCKS mRNA expression in primary 
culture cells
Using semi-quantitative RT-PCR, the mRNA levels of
NUCKS were evaluated in primary culture cells. The clin-
icopathological parameters of breast biopsies used for pri-
mary cultures are summarized in Additional file 1. In
Figure 4, the representative results of each clinicopatho-
logical category are demonstrated. Specifically, in the pri-
mary cultures from normal tissues and fibroadenomas,
NUCKS mRNA was detected at low levels. In the cultures
derived from tissues with benign lesions, NUCKS mRNA
varied from low levels, as observed in normal tissues and
fibroadenomas, to higher levels resembling some cases of
IDC, grade II. In most of the cultures derived from grade
II tumors, NUCKS mRNA was significantly increased com-
pared to normal. However, there were some cultures from
grade II carcinomas exhibiting low NUCKS mRNA levels.
The observed variation of NUCKS mRNA in primary cul-
tures from benign and grade II biopsies is concomitant to
immunohistochemical results from the corresponding
biopsies (Tables 1 and 2) and may be related to tumor
heterogeneity. In most of the cultures derived from biop-
sies of IDC, grade III, NUCKS mRNA levels were lower
than that observed in primary cultures from IDC, grade II,
while in few cases the levels of NUCKS mRNA expression
were significantly higher.
Table 1: Analysis of NUCKS immunostaining in non malignant, non metastatic breast lesions
Fibroepithelial
tumours
(n=13)
Benign epithelial 
proliferations
(n = 31)
Intraductal proliferative lesions
(n = 38)
Overall NUCKS
Immuno-
Reactivity
Fibroadenoma 
(n = 13) 
RR = ns
Adenosis 
(n = 20) 
RR = ns
Sclerosing 
adenosis 
(n = 11)
R = ns
Usual ductal 
hyperplasia, UDH
(n = 16), RR = 1.5
Atypical ductal 
hyperplasia, ADH,
(n = 6), 
RR = 4.0–5.0
Ductal carcino-
mas in situ, DCIS 
(n = 16), 
RR = 8.0–11.0
Negative (0) 13(100%) 3 (15%) 1 (9%) 3 (19%) 1 (6%)
+1 10 (50%) 6(55%) 8 (50%) 1 (17%) 2 (12%)
+2 6 (30%) 4(36%) 4 (25%) 2 (33%) 6 (38%)
+3 1 (5%) 1 (6%) 3 (50%) 7 (44%)
Low expression
(0/+1)
13 (100%) 13 (65%) 7 (64%) 11 (69%) 1 (17%) 3 (18%)
High expression 
(+2/+3)
7 (35%) 4 (36%) 5 (31%) 5 (83%) 13 (82%)
RR = relative risk for subsequent development of invasive breast cancer; ns = non significantPage 3 of 14
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resembled the expression pattern in the corresponding
biopsies, verifying that primary cultures retain most of the
aspects of the primary tumors of origin.
Quantitation of NUCKS mRNA levels
Quantitative, real-time RT-PCR analysis of primary cul-
ture cells derived from benign lesions and breast carcino-
mas revealed higher NUCKS gene expression compared to
normal and fibroadenoma culture cells (Figure 5). The
median relative NUCKS mRNA/PBGD mRNA ratio was
5.346 (range, 3.821–6.897) for normal and 6.328 (range,
5.727–7.583) for fibroadenoma samples. Significantly
higher ratio of NUCKS mRNA/PBGD mRNA was observed
in benign lesions [median relative ratio 23.114 (range,
5.942–32.241)], as well as in grade II samples [median
relative NUCKS mRNA/PBGD mRNA ratio 38.212 (range,
10.594–46.604)], whereas the median relative NUCKS
mRNA/PBGD mRNA ratio of grade III samples was
30.962 (range, 20.929–35.390).
Western immunoblot analysis
As shown in Figure 6, the levels of the NUCKS protein in
primary cultures demonstrated a similar expression pat-
tern compared to immunohistochemistry (Figures 1, 2),
as well as to RT-PCR (Figure 4) and qRT-PCR (Figure 5).
Specifically, in the primary cultures from normal tissues
and fibroadenomas, the NUCKS protein levels were non
detectable. In primary cultures from benign lesions,
NUCKS protein levels demonstrated a variation from non
detectable to higher levels. The majority of cultures
derived from grade II tumors showed increased levels of
NUCKS protein compared to few ones exhibiting low to
non detectable protein levels. However, in the primary
cultures derived from IDC, grade III biopsies the NUCKS
protein levels were lower than most of grade II and benign
proliferation samples.
The correlation between NUCKS mRNA and protein levels
in each examined sample showed limited variation,
except for grade III biopsies. Specifically, there was a direct
correlation between mRNA and protein levels in normal,
fibroadenoma, proliferative lesions and grade II primary
cancer samples in contrast to grade III samples where
NUCKS mRNA levels were significantly higher than pro-
tein levels. Actually, this finding was in full agreement
with the immunohistochemical results from the corre-
sponding IDC, grade III biopsies which stained for
NUCKS with a score of +1, compared to most of the
benign proliferations and grade II biopsies which stained
with a score of +2 to +3. All primary cultures from benign
lesions derived from biopsies with UDH along with ade-
nosis and/or sclerosing adenosis. In these cultures there
was direct correlation between mRNA levels (as evaluated
with RT-PCR and qRT-PCR) and protein levels (as evalu-
ated with western immunoblot and immunohistochemis-
try).
Correlation between NUCKS and Ki67 expression
Since NUCKS is believed to be important in cell cycle pro-
gression, in order to verify that the observed NUCKS over-
expression in non malignant and malignant lesions was
not a result of enhanced proliferation, Ki67 expression
Immunohistochemical staining of non malignant breast tissue biopsies wi h anti-NUCKS and anti-ki67 antibodyFigur  1
Immunohistochemical staining of non malignant 
breast tissue biopsies with anti-NUCKS and anti-ki67 
antibody. Tissue sections stained with anti-NUCKS (A-D) 
and corresponding sections stained with anti-ki67 (E-H) anti-
body. (A), (E), Normal breast tissue exhibiting negative stain-
ing for both NUCKS and Ki67. (B), (F) Fibroadenoma 
exhibiting negative staining for NUCKS and low staining for 
Ki67. (C), (G) Sclerosing adenosis exhibiting strong staining 
for NUCKS and negative staining for Ki67. (D), (H) Strong 
immunoreaction for NUCKS in ADH and low for Ki67. Scale 
bar, 50 μm.Page 4 of 14
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Table 2: Analysis of NUCKS immunostaining in invasive breast carcinomas
Overall NUCKS immuno-
Reactivity
IDC, ILC, grade I 
(n = 9)*
IDC, ILC, grade II 
(n = 41)**
IDC, grade III 
(n = 8)
Negative (0) 3 (33.5%) 4 (10%) 2 (25%)
+1 3 (33.5%) 9 (22%) 5 (62,5%)
+2 2 (22%) 12 (29%) 1 (12,5%)
+3 1 (11%) 16 (39%) 0
Low expression (0/+1) 6 (67%) 13 (32%) 7 (87,5%)
High expression (+2/+3) 3 (33%) 28 (68%) 1 (12,5%)
* The 9 cases of grade I consisted of 8 IDC and 1 ILC
* The 41 cases of grade II consisted of 35 IDC and 6 ILC
Immunohistochemical staining of DCIS and IDC with anti-NUCKS and anti-k 67 antibodyFigure 2
Immunohistochemical staining of DCIS and IDC with 
anti-NUCKS and anti-ki67 antibody. Tissue sections 
stained with anti-NUCKS (A-C) and corresponding sections 
stained with anti-ki67 (D-F) antibody. (A), (D), Strong immu-
noreaction for NUCKS and low for Ki67 in DCIS. (B), (E) 
Strong immunoreaction for NUCKS and low for Ki67 in IDC, 
grade II. (C), (F) IDC, grade III negative staining for NUCKS 
and strong staining for Ki67. Scale bar, 50 μm.
The epithelial origin of the primary culture cellsFigure 3
The epithelial origin of the primary culture cells. (A) 
Phase contrast micrograph showing epithelial cells derived 
form the tissue fragment of the breast cancer biopsy. The 
cells are polygonal and have pleomorphic nuclei with promi-
nent nucleoli. (B) Electron micrograph showing the contact 
of adjacent epithelial breast neoplastic cells through the for-
mation of tight junctions and desmosomes (arrows) which 
delineate intercellular lumina (IL) lined by protruding micro-
villi. N; nucleus. (C) immunofluorescence micrograph of cells 
from primary culture showing cytoplasmic localization of 
CK8 with varying intensity. (D) Cells were counterstained 
with DAPI. (E) Merged immunofluorescence micrographs of 
cytokeratin 8 localization and DAPI revealing the cytoplasmic 
localization of CK8 in the entire cell population verifying 
their epithelial origin. Original magnification: (a) ×400×, (b) 
×15,400, (c-e) ×200.
Cancer Cell International 2009, 9:19 http://www.cancerci.com/content/9/1/19was studied by means of immunohistochemistry and
immunofluorescence in tissue sections and primary cul-
tures respectively.
In the tissue sections from benign epithelial prolifera-
tions, where NUCKS is found to be overexpressed, Ki67
expression was low with less than 10% of the cell nuclei
staining positively (Figures 1E–1H). On the contrary, in
some cases of IDC, grade II and III, there was an increased
expression of Ki67 (>10%) whereas NUCKS expression
was low (Figure 2C, 2F). However, in some cases of IDC,
grade II, there was an increased expression of both
NUCKS (score +2, +3) and Ki67 (>10%). Statistical anal-
ysis revealed no apparent correlation between NUCKS
and Ki67 expression (p = 0.10). Moreover, in all of the pri-
mary cultures developed, Ki67 was scarcely expressed
(Figure 7C). On the contrary, all of the cells in the primary
culture exhibited variable but detectable levels of NUCKS
(Figure 7B) indicating that NUCKS expression is not nec-
essarily related with cell proliferation in breast cancer.
Discussion
The results show that there is an increased NUCKS expres-
sion in breast cancer compared to normal tissue. More
specifically, the immunohistochemical results show that
the percentage of NUCKS positive cases in invasive breast
Semi-quantitative mRNA expression of NUCKS in primary cultures from different biopsiesFigure 4
Semi-quantitative mRNA expression of NUCKS in primary cultures from different biopsies. (A) The RT-PCR 
products, generated with NUCKS and GAPDH gene specific primers, were electrophorized in a 2% agarose gel. GAPDH mRNA 
was used as an internal control. The most representative cases are illustrated. (B) Graphical presentation of the ratio of NUCKS 
to GAPDH mRNA levels corresponding to the samples illustrated in (A), as median values of 3 independent experiments (p = 
0.05). The mRNA levels were quantitated semiquantitatively as described in the Methods section. TC01, primary culture of 
normal tissue; TC05, primary culture of fibroadenoma; TC11 and TC13, derived from primary cultures from biopsies with 
benign epithelial proliferations; TC16, TC20, TC27-TC31 derived from primary cultures from IDC, grade II biopsies; TC32 and 
TC36 derived from IDC, grade III. The clinicopathological variables of the samples are summarized in Additional file 1. MDA 
MB-231 and MCF-7 represent cell lines used as a positive control for NUCKS expression. (C) Median values of the ratio of 
NUCKS to GAPDH mRNA levels in the studied groups (p = 0.05).Page 6 of 14
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90%) and III (6/8, 75%) carcinomas compared to normal
cases. NUCKS is also overexpressed in many of the benign
epithelial proliferations and intraductal lesions examined
in this study. It is worth mentioning that the cases of ADH
and DCIS showed intense staining of NUCKS. On the
contrary, all the fibroadenomas and the majority of the
lobular carcinomas stained negatively for NUCKS. These
results are confirmed by RT-PCR, qRT-PCR and Western
immunoblot analyses from the primary cultures.
The NUCKS gene is located on chromosome 1q32.1.
There are several scientific reports utilizing array-based
Comparative Genomic Hybridization (CGH) techniques,
which show that there is a high frequency (59–74%) of
gain of chromosome region 1q.32 in breast cancer and
this gain is an early event in the cancer progression [16-
21]. Most of the reports show that lobular carcinomas
exhibit a higher frequency of gain of chromosomal region
1q.32 (74%) compared to ductal (59%), having however
a lower total number of genetic aberrations compared to
ductal carcinomas [16-21]. Furthermore, a number of
genetic aberrations have been described in fibroadeno-
mas, but none of them include the gain of chromosomal
region 1q32 [22]. These data could explain the upregula-
tion of NUCKS in ductal breast cancer as validated from
the present study, and also the finding that all the fibroad-
enomas evaluated stained negatively for NUCKS. How-
ever, most of the lobular carcinomas stained negatively
for NUCKS. It could be hypothesized that gain of chromo-
somal region 1q32 is a prerequisite but not sufficient for
the increase of NUCKS expression, and that an additional
background of genetic aberrations and instability is
responsible for triggering the upregulation of NUCKS
mRNA and protein.
Noteworthy, there was a correlation between NUCKS
overexpression and grading of DCIS. Low grade, well dif-
ferentiated DCIS exhibited intense staining for NUCKS
like the majority of ADH lesions. On the contrary, high
grade poor differentiated DCIS, like most of the IDC,
grade III cases, exhibited weak to moderate NUCKS stain-
ing. This finding is in accordance with the view of Simp-
son et al [23] that ADH and low grade DCIS show highly
similar pathological and genetic features and constitute a
distinct entity, whereas high grade DCIS and grade III car-
Quantitative mRNA expression of NUCKS in primary cultures from different biopsiesFigure 5
Quantitative mRNA expression of NUCKS in primary cultures from different biopsies. (A) Graphical presentation 
of the ratio of NUCKS to PBGD mRNA expression quantitated by qRT PCR as median values of 3 independent experiments (p 
= 0.05) per culture. The most representative cases are illustrated. TC01, primary culture of normal tissue; TC05, primary cul-
ture of fibroadenoma; TC11 and TC13, derived from primary cultures from biopsies with benign epithelial proliferations; 
TC16, TC20, TC27-TC31 derived from primary cultures from grade II breast cancer biopsies; TC32 and TC36 derived from 
IDC, grade III. The clinicopathological variables of the samples are summarized in Additional file 1. MDA MB-231 and MCF-7 
represent cell lines used as a positive control for NUCKS expression. (B) Median values of the ratio of NUCKS to PBGD mRNA 
expression in the studied groups (p = 0.05).Page 7 of 14
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entity.
NUCKS has been characterized as a cell cycle related pro-
tein synthesized during the M/G1 phase [7]. However, the
fact that its expression is not correlated with Ki67 prolifer-
ating index, neither in breast tissue biopsies nor in pri-
mary culture cells, as demonstrated in the present study,
implies that NUCKS has a more complex role than just
promoting cell proliferation. Moreover, there are a
number of scientific data indicating that NUCKS could
play a role in the DNA damage response. Although
NUCKS sequence shares no homology with any other
protein in protein databases or translated cDNA databases
[24], it exhibits a slight homology with RAD51AP1, a
nucleic acid binding protein interacting with Rad51
recombinase in maintaining genomic integrity and possi-
bly implicated in DNA damage response [25]. Further-
Western immunoblot analysis of NUCKS in primary cultures from different biopsiesFigure 6
Western immunoblot analysis of NUCKS in primary cultures from different biopsies. (A) Equal amounts of total 
protein (30 μg) were subjected to immunoblot analysis with anti-NUCKS antibody. After stripping, the membrane was rep-
robed with anti-actin antibody. Actin protein was used as an internal control and in order to verify equal loading of the gel. 
MDA MB-231 and MCF-7 cell lines were used as a positive control. The most representative cases are illustrated. (B) Graphical 
presentation of the ratio of NUCKS to actin protein levels corresponding to the samples illustrated in (A), as median values of 
2 independent experiments (p = 0.05). The protein levels were calculated from the immunoblot reaction with the Image-Pro 
Plus software, as described in the Methods section. TC01, primary culture of normal tissue; TC05, primary culture of fibroad-
enoma; TC11 and TC13, derived from primary cultures from biopsies with benign epithelial proliferations; TC16, TC20, TC27-
TC31 derived from primary cultures from grade II breast cancer biopsies; TC32 and TC36 derived from IDC, grade III. 
NUCKS protein levels resemble its mRNA expression, exhibiting the same variation among the different samples except for 
IDC grade III. MDA MB-231 and MCF-7 represent cell lines used as a positive control for NUCKS expression. The clinico-
pathological variables of the samples are summarized in Additional file 1. (C) Median values of the ratio of NUCKS to actin pro-
tein levels in the studied groups (p = 0.05).Page 8 of 14
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mutated) and ATR (ATM and Rad3-related) kinases after
irradiation of 293T cells [26], implying that NUCKS is a
cell cycle related protein involved in DNA damage
response. Since the activation of the DNA damage check-
point is an early event in carcinogenesis [27], it could be
proposed that the observed NUCKS overexpression in
benign epithelial proliferations and intraductal lesions is
related with the activation of DNA damage checkpoints.
Gene expression profiling of breast tumors is a novel tool
in the effort to classify tumor subtypes, predict risk of
relapse, identify genes that mediate disease progression
and select optimal therapeutic options [28]. Among the
gene signatures established so far concerning breast cancer
(for a complete review see [29]), NUCKS has been found
to correlate with the invasive gene signature (IGS) [30].
The IGS consists of 186 genes which are overexpressed in
breast cancer stem cells identified by high expression of
CD44 and low expression of CD24 (CD44+CD24-/low),
compared to normal breast epithelial cells. The
CD44+CD24-/low cells represent a small subclass within
the tumor but are considered to be the actual tumorigenic
cells whereas the rest, called nontumorigenic, have little
or no such ability. The fact that NUCKS belongs to IGS
demonstrates its important role in breast cancer but fur-
ther investigation is needed in order to elucidate whether
the observed overexpression in breast cancer is correlated
with oncogenic progression and poor prognosis or reflect
a preventive response to cancer-related genomic instabil-
ity.
There is still much work to be done on elucidating the
mechanisms by which NUCKS contributes to oncogenesis
so that in the long term this protein could serve as a
potential prognostic marker for breast cancer progression.
Conclusion
For the first time, an evaluation of NUCKS protein levels
is made in association with the histopathological types
and grade by means of immunohistochemical, biochemi-
cal and molecular techniques applied on benign, intra-
ductal and cancerous breast lesions. The results show
overexpression of the NUCKS protein in a number of non
malignant breast lesions and cancerous tissues. In partic-
ular, the NUCKS overexpression in ADH and DCIS indi-
cates a future significant role of this protein in evaluating
neoplastic progression.
Methods
Archival material
The material of this study was obtained from Evgenidion
University Hospital and consisted of 91 paraffin blocks
from female patients who underwent diagnostic biopsy or
radical mastectomy from 2004 onwards. All the breast tis-
sues biopsies were histological classified according to cur-
rent World Health Organization (WHO) scale [15]. The
tissue biopsies included 20 cases of benign epithelial pro-
liferations (adenosis and sclerosing adenosis), the major-
ity of which coexisted with usual ductal hyperplasia
(UDH); 13 cases of fibroadenomas; 8 cases of IDC, grade
I; 35 cases of IDC, grade II; 8 cases of IDC, grade III; 1 case
of ILC, grade I and 6 cases of ILC, grade II. Sixteen ductal
carcinoma in situ cases (DCIS) co-existing with IDC
lesions of different histological grading were also studied.
Specifically, 2 cases of DCIS were co-existed with IDC,
grade I; 12 cases of DCIS were co-existed with IDC, grade
II and 2 cases of DCIS were co-existed with IDC, grade III.
Furthermore, among the studied material, 6 cases of atyp-
ical ductal hyperplasia (ADH) were encountered as com-
ponents of some of the above lesions. Particularly, 1 case
of ADH co-existed with benign lesions; 1 case with IDC,
grade I; 3 cases with IDC, grade II and 1 case with IDC,
Immunofluorescence expression of NUCKS and Ki67 in a representative primary culture derived from IDC, grade IIFigure 7
Immunofluorescence expression of NUCKS and Ki67 in a representative primary culture derived from IDC, 
grade II. The scarce expression of Ki67 and the ubiquitous expression of NUCKS are demonstrated. (A), cells counterstained 
with DAPI. (B), NUCKS expression in all of the cell nuclei. (C), only one cell in the optical field expressing Ki67 (arrow). Orig-
inal magnification ×200.Page 9 of 14
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was evaluated according to Holland et al [31]. The histo-
logical grading of invasive breast carcinomas was evalu-
ated according to the modified Scarff-Bloom-Richardson
histological grading system with guidelines as suggested
by Nottingham City Hospital pathologists [32].
The normal breast tissues refer to areas of paraffin sections
next to benign epithelial proliferations. Information on
axillary lymph node status was available in all cases.
Biomarkers concerning ER, PR and HER-2/neu were pro-
vided from the Pathology Department of Evgenidion Hos-
pital. All investigational biopsies were approved by the
Athens Medical School Ethical Committee (approval
no.5758/12-3-03).
Primary cell cultures
For primary cell culturing, 33 breast tissue biopsies were
obtained and processed-in parallel to the paraffin embed-
ding procedure- as previously described [33]. In addition,
3 biopsies of normal tissue derived from areas adjacent to
benign epithelial proliferations were also processed for
primary culturing. From each biopsy, several small (2–3
mm3) tissue fragments were placed onto plastic Petri
dishes 35 mm in diameter and cultured in RPMI 1640
supplemented with 10% Fetal Calf Serum (FCS), 1 mM L-
glutamine, 1% penicillin and 1% streptomycin, at 37°C,
under 5% CO2. The cells were allowed to migrate out of
the tissue fragment using the explant technique, without
any mechanical or enzymatic tissue disaggregation. The
cell growth was complete in about 2–3 weeks. The tissue
biopsies were marked as TC01-TC36 [see Additional file
1].
Cell culturing and further processing of the tissue were
carried out at the Laboratory of Histology and Embryol-
ogy, Medical School, University of Athens.
Cell line cultures
The human breast cancer cell lines MDA-MB-231 and
MCF-7 were used as positive controls for NUCKS expres-
sion. MCF-7 cell line was also used as a positive control
for cytokeratin 8 (CK8) and Ki67 expression using indirect
immunofluorescence. The cells were grown in RPMI 1640
medium supplemented with 10% Foetal Calf Serum
(FCS), 1 mM L-glutamine, 1% penicillin, and 1% strepto-
mycin. Cells were incubated at 37°C, under 5% CO2.
Transmission electron microscopy
For the ultrastructural confirmation of the epithelial ori-
gin, cells of primary cultures were fixed in 2.5% glutaral-
dehyde made up in phosphate buffer saline (PBS) 0.01 M,
pH 7.4, for 15 min at room temperature, postfixed in 1%
aqueous OsO4 for 30 min at 4°C, isolated according to
Kouloukoussa et al. [34] and were finally embedded in a
mixture of epoxy resins. Ultrathin (80–90 nm thick) sec-
tions were cut with a Diatome diamond knife on a Leica
Ultracut R ultramicrotome and were collected onto 200
mesh uncoated copper grids.
Paraffin immunohistochemistry
The preparation of the antibody against NUCKS protein
has been described in details in Østvold et al, 2001 [4]
and it has been used in several publications [11,24]. In the
present study, the specificity of the Ab was first checked in
immunoblot with protein extracts from MCF-7 cells.
Tissue sections (5 μm thick) were obtained from repre-
sentative formalin-fixed paraffin-embedded tissue blocks
from each patient. The sections were mounted on Super-
frost® slides and deparaffinized by heating at 60°C for 30
min followed by immersion in xylene for 2 × 10 min and
rehydrated by immersion in 100% ethanol for 2 × 5 min,
95% ethanol for 5 min, 70% ethanol for 5 min, 50% eth-
anol for 5 min and dH2O for 2 × 5 min. In order to inac-
tivate endogenous peroxidase activity, the slides were
incubated in 3% H2O2 for 30 min followed by immersion
in dH2O 3 × 5 min. Antigen retrieval was performed by
trypsin (0,1% trypsin in 0,1% CaCl, 20 mM Tris-Cl, pH
7,8) digestion for 10 min at 37°C. The slides were rinsed
with tap water for 5 min followed by immersion in dH2O
for 3 × 5 min and in PBS for 3 × 5 min. The slides were
then incubated with blocking solution PBS, 1% BSA, 5%
NGS for 1 h at RT followed by incubation with primary
affinity purified rabbit anti-NUCKS Ab (1:300) in PBS,
1% BSA, 5% NGS overnight at 4°C. The next day, the
slides were rinsed in PBS for 3 × 5 min and incubated with
HRP conjugated secondary goat anti-rabbit Ab (1:100) in
PBS, 1% BSA for 1 h at RT, followed by immersion in PBS
for 3 × 5 min. The signal was visualized with DAB chro-
mogen (0.05% DAB, 0.024% H2O2 in PBS). The slides
were then stained with hematoxylin, dehydrated in alcho-
hol, immersed in xylene and finally coverslipped. As neg-
ative controls, paraffin sections were treated with the same
immunohistochemical protocol, but instead of primary
Ab, were incubated with PBS, 5% NGS, 1% BSA. As posi-
tive controls, paraffin sections of whole rat embryo E13,5
p.c were used [4]. The sections were photographed under
a LEICA DM LB2 photomicroscope, equipped with a DFC
320 digital camera.
Immunoreactivity was evaluated in 10 high power fields
as follows: A score of 0 was given if fewer than 10% of pos-
itive nuclei of epithelial cells were detected; score 1 if 11%
to 30% were detected with low staining intensity; score 2
if more than 30% and less than 60% of positive nucleiPage 10 of 14
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3 if more than 60% of positive nuclei were detected with
high staining intensity.
Immunofluorescence of primary culture cells
Primary culture cells grown on sterilized glass coverslips
were fixed for 20 min in 4% paraformaldehyde, washed in
PBS and permeabilized for 5 min in 0.2% Triton X-100 in
PBS. The cells were washed 3 times over 5 min in PBS and
incubated with affinity purified rabbit anti-NUCKS anti-
body (1:600) and mouse anti-Ki67 antibody (clone: MIB-
1, M7240, DAKO) (1:400), or mouse anti-cytokeratin 8
(1:100) (C5301, Sigma) for 1 h at room temperature. The
cells were then washed 3 times over 5 min with PBS and
incubated for 30 min at room temperature, with a mixture
of Alexa-488 conjugated donkey anti-rabbit IgG antibody
(1:150) and CF™555-conjugated donkey anti-mouse IgG
antibody (1:200). DAPI was used as a counterstain.
Stained slides were examined in a Nikon Eclipse TE 2000-
S fluorescent microscope.
RNA isolation-cDNA synthesis
Total cellular RNA was extracted from primary culture
cells and cell lines by TRizol reagent according to the man-
ufacturer's instructions (Invitrogen) and in vitro tran-
scribed to cDNA using Moloney Murine Leukaemia Virus
reverse transcriptase (RT) and random hexamers as prim-
ers. As a control for the presence of amplifiable cDNA,
retinoic acid receptor alpha sequences (RARα) were
amplified in separate reactions as previously described
[35]. Both in the RT reaction and in the ensuing amplifi-
cation reactions, recommended measures to prevent
cross-contamination of samples were followed. In addi-
tion, for each experiment, a control with no template was
used to check for the presence of any contaminant.
PCR amplification of NUCKS cDNA sequences
Ten microliters of the RT reaction was amplified by PCR
using oligonucleotides specific for the NUCKS gene. PCR
was carried out in a final volume of 100 μl, with 50 pmol
of each oligonucleotide primer, 200 μmol/l each of dNTP,
1 U of Go Taq Flexi polymerase (Promega) in PCR buffer
(20 mM Tris-HCl, pH 8.4, 50 mM KCl, 1.5–2.0 mM
MgCl2). The amplification condition were 94°C for 3
min, 30 cycles of 94°C for 30 sec, 60°C for 30 sec, 72°C
for 1 min and finally 72°C for 10 min. The sequences of
the PCR primers used for amplification of NUCKS cDNA
are shown in Table 3.
Determination of the specific PCR products was also per-
formed using direct sequencing. For the sequencing anal-
ysis, PCR specific bands were isolated and purified from
3% low melting point agarose gel and sequenced by the
dideoxy-chain termination method using the modified
version of T7 DNA polymerase (Sequenase 2.0, US Bio-
chemicals, Cleveland, Ohio, USA).
Semi-quantitative RT-PCR
Amplification of a product corresponding to a region
from exon 3 to exon 7 of the NUCKS cDNA sequence was
performed as described above. In parallel, a GAPDH
mRNA transcript was amplified from the same samples
(nucleotide sequences of the primers are shown in Table
3). The amplified products were electrophorised in a 2%
agarose gel, stained with ethidium bromide, photo-
graphed under UV illumination and the images were dig-
itally captured. All experiments were performed in
triplicates.
The images were analyzed using the Image-Pro Plus, ver-
sion 3.0, software for Windows (Media Cybernetics, Silver
Table 3: Primers and probes for semi-quantitative and real-time PCR
Oligonucleotide Sequence
NUCKS F (forward) 5'-AATTCACAGGAAGATAGTGAGG-3'
NUCKS R (reverse) 5'-TCACTGTAG CCTTTAGTCTGGG-3'
GAPDH forward 5'-ATGGGGAAGGTGAAGGTCGGAGTC-3'
GAPDH reverse 5'-GAACATGGGGGCGTCAGCAGAG-3'
NUCKS Fq (forward, real-time PCR) 5'-TCTGATGATGCAGATGAAGATTA-3'
NUCKS Rq (reverse, real-time PCR) 5'-CTGCTGAGTGAGAATCATCC-3'
NUCKS FL probe 5'-TCTTGGTCTTCACATCTTTGTCTTCT-FL-3'
NUCKS LC probe 5'-LC640-AGTCCTCACTATCTTCCTGTGAATTCTTT-3'Page 11 of 14
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PCR products was calculated. Each sample was tested at
least twice. The amount of cDNA corresponding to the
NUCKS gene in each sample was determined by identifi-
cation of the ratio of the intensity of the band correspond-
ing to each sample to that of GAPDH.
Quantitative, real-time PCR (qRT-PCR) assessment of 
NUCKS mRNA expression
In order to quantitate NUCKS mRNA transcripts, real-
time fluorescence PCR assays were developed and evalu-
ated for the Roche LightCycler (LC; Roche Diagnostics).
After adding 180 μL water to the reverse transcription
reaction product, 2 μL aliquots were used for each reac-
tion. In a separate PCR reaction, the same cDNA was eval-
uated for expression of the porphobilinogen deaminase
(PBGD) gene using the LightCycler(r) h-PBGD House-
keeping Gene Set (Roche). The amplification mixture con-
sisted of 2 μL of 10× reaction mix (LC-FastStart master
hybridization probes; Roche Diagnostics), 2 mM MgCl2,
0.5 μM concentration of each oligonucleotide primer,
0.15 μM concentration of each oligonucleotide probe,
and 2 μL of template cDNA in a final volume of 20 μL.
Samples were amplified as follows: an initial denaturation
step at 95°C for 3 min to activate the FastStart Taq DNA
polymerase, 40 cycles of denaturation at 95°C for 10 sec,
annealing at 51°C for 15 sec and extension at 72°C for 15
sec. The temperature transition rate was 20°C/sec. All
experiments were performed in triplicates.
DNA oligonucleotide primers and hybridization probes
were synthesized by TIB Molbiol (Berlin, Germany). The
adjacent ends of the hybridization probes were labelled
with fluorophores. The 5' end of the first probe was
labelled with the acceptor fluorophore LC Red 640 and
the 3' end of the second probe with the donor fluorescein
(FITC, 3FL). The 5' labelled probes were 3'- phosphor-
ylated to block polymerase extension during PCR. Nucle-
otide sequences of the primers and hybridization probes
are shown in Table 3.
Western immunoblot analysis
Cell harvesting, sample processing, electrophoresis and
immunoblot were performed as previously described
[33]. In brief, 30 μg of total protein were loaded from each
sample and resolved on 15% polyacrylamide SDS gel.
After blocking, the membranes were incubated overnight
at 4°C with rabbit anti- human NUCKS (1:2,000) anti-
body. The reaction was visualized with ECL Plus (Amer-
sham) on Kodak Biomax XAR films. In order to verify
equal loading, the membranes were stripped and re-
probed with mouse anti-human actin (1:3,000)
(MAB1501, Chemicon). All experiments were performed
in duplicates. The films were scanned and densitometric
measurements for NUCKS and actin bands were per-
formed as for RT-PCR.
Statistical analysis
The chi-square test was used to analyze the correlation
between NUCKS expression by immunohistochemistry
and clinicopathological features. P values of less than 0.05
were considered significant.
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